The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
Open accessAbstract
Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. Because injury and/or regeneration of type II pneumocytes are prominent histological features of ILDs, substances derived from type II pneumocytes have been the focus of research investigating potential biomarkers for ILD. One important biomarker for ILD is the high-molecular-weight glycoprotein, Krebs von den Lungen-6 (KL-6). KL-6 is now classified as a human MUC1 mucin protein, and regenerating type II pneumocytes are the primary cellular source of KL-6/MUC1 in the affected lungs of patients with ILD. KL-6/MUC1 is detectable in the serum of patients with ILD, and extensive investigations performed primarily in Japan have revealed that serum KL-6/MUC1 is elevated in 70-100% of patients with various ILDs, including idiopathic interstitial pneumonias, collagen vascular disease-associated interstitial pneumonia, hypersensitivity pneumonia, radiation pneumonitis, drug-induced ILDs, acute respiratory distress syndrome, pulmonary sarcoidosis, and pulmonary alveolar proteinosis. The results from these various studies have supported the utility of KL-6/MUC1 as a serum biomarker for detecting these various ILDs. Moreover, KL-6/MUC1 serum levels have been demonstrated to be useful for evaluating disease activity and predicting the clinical outcomes of various ILD types. Based on these observations, we believe that KL-6/MUC1 is currently one of the best and most reliable serum biomarkers available for ILD management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
sarcoidosis, S. O. (1999) · American Journal of Respiratory and Critical Care Medicine · Cited by 1,953
(1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.ats4-99 · Cited by 1,902
international consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
Structure and Function of the Cell Surface (Tethered) Mucins
Hattrup, C. L., & Gendler, S. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100659 · Cited by 779
New Serum Indicator of Interstitial Pneumonitis Activity
Nobuoki, K., Seishi, K., Yukikazu, A., Hirofumi, F., Michio, Y., & Mitoshi, A. (1989) · Chest · doi:10.1378/chest.96.1.68 · Cited by 486
Kitler, M. E. (2005) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200519040-00007 · Cited by 480
Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1501oc · Cited by 477
Cell surface-associated mucins in signal transduction
Singh, P. K., & Hollingsworth, M. A. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.006 · Cited by 422
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
OHNISHI, H., YOKOYAMA, A., KONDO, K., HAMADA, H., ABE, M., NISHIMURA, K., HIWADA, K., & KOHNO, N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.3.2107134 · Cited by 398
Self-citationClinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases
King, T. E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200503-483oe · Cited by 330
Prognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis
YOKOYAMA, A., KONDO, K., NAKAJIMA, M., MATSUSHIMA, T., TAKAHASHI, T., NISHIMURA, M., BANDO, M., SUGIYAMA, Y., TOTANI, Y., ISHIZAKI, T., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00834.x · Cited by 304
Self-citationGuidelines for the clinical evaluation of hypersensitivity pneumonitis
Richerson, H. B., Bernstein, I. L., Fink, J. N., Hunninghake, G. W., Novey, H. S., Reed, C. E., Salvaggio, J. E., Schuyler, M. R., Schwartz, H. J., & Stechschulte, D. J. (1989) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(89)90349-7 · Cited by 303
Kohno, N., Awaya, Y., Oyama, T., Yamakido, M., Akiyama, M., Inoue, Y., Yokoyama, A., Hamada, H., Fujioka, S., & Hiwada, K. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.3.637 · Cited by 286
Self-citationSerum Indicators for the Diagnosis of Pneumocystis Pneumonia
Tasaka, S., Hasegawa, N., Kobayashi, S., Yamada, W., Nishimura, T., Takeuchi, T., & Ishizaka, A. (2007) · Chest · doi:10.1378/chest.06-1467 · Cited by 263
Hypersensitivity pneumonitis: current concepts
Bourke, S. J., Dalphin, J. C., Boyd, G., McSharry, C., Baldwin, C. I., & Calvert, J. E. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.18s320081 · Cited by 252
KL-6: A Serum Marker for Interstitial Pneumonia
Kobayashi, J., & Kitamura, S. (1995) · Chest · doi:10.1378/chest.108.2.311 · Cited by 219
Oligosaccharides Expressed on MUC1 Produced by Pancreatic and Colon Tumor Cell Lines
Burdick, M. D., Harris, A., Reid, C. J., Iwamura, T., & Hollingsworth, M. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24198 · Cited by 215
Tumor Necrosis Factor-α Converting Enzyme/ADAM 17 Mediates MUC1 Shedding
Thathiah, A., Blobel, C. P., & Carson, D. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208326200 · Cited by 211
Circulating KL-6 Predicts the Outcome of Rapidly Progressive Idiopathic Pulmonary Fibrosis
YOKOYAMA, A., KOHNO, N., HAMADA, H., SAKATANI, M., UEDA, E., KONDO, K., HIRASAWA, Y., & HIWADA, K. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.5.9803115 · Cited by 211
Self-citationKL-6, a Human MUC1 Mucin, Is Chemotactic for Human Fibroblasts
Hirasawa, Y., Kohno, N., Yokoyama, A., Inoue, Y., Abe, M., & Hiwada, K. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.17.4.2253 · Cited by 179
Self-citationHANT, F. N., LUDWICKA-BRADLEY, A., WANG, H.-J., LI, N., ELASHOFF, R., TASHKIN, D. P., & SILVER, R. M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080633 · Cited by 177
Ishizaka, A., Matsuda, T., Albertine, K. H., Koh, H., Tasaka, S., Hasegawa, N., Kohno, N., Kotani, T., Morisaki, H., Takeda, J., et al. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00420.2002 · Cited by 176
Self-citationIncreased levels of KL‐6 and subsequent mortality in patients with interstitial lung diseases
SATOH, H., KURISHIMA, K., ISHIKAWA, H., & OHTSUKA, M. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01704.x · Cited by 171
Antoniou, K. M., Margaritopoulos, G., Economidou, F., & Siafakas, N. M. (2009) · European Respiratory Journal · doi:10.1183/09031936.00152607 · Cited by 162
The Estimated Incidence of Cystic Fibrosis in Japan
Yamashiro, Y., Shimizu, T., OGUCHI, S., SHIOYA, T., Nagata, S., & Ohtsuka, Y. (1997) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199705000-00010 · Cited by 155
The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults
B. T. SOCIETY (1999) · Thorax · doi:10.1136/thx.54.suppl_1.s1 · Cited by 147
Circulating KL-6 levels in patients with drug induced pneumonitis
Ohnishi, H. (2003) · Thorax · doi:10.1136/thorax.58.10.872 · Cited by 144
Ishii, H., Mukae, H., Kadota, J., Kaida, H., Nagata, T., Abe, K., Matsukura, S., & Kohno, S. (2003) · Thorax · doi:10.1136/thorax.58.1.52 · Cited by 135
Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines.
Kondo, K., Kohno, N., Yokoyama, A., et al. (1998) · PubMed · Cited by 134
Self-citationYanaba, K., Hasegawa, M., Takehara, K., et al. (2004) · PubMed · Cited by 122
KL‐6 levels are elevated in plasma from patients with acute respiratory distress syndrome
Satō, H., Callister, M. E. J., Mumby, S. E., Quinlan, G. J., Welsh, K. I., du Bois, R. M., & Evans, T. W. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00070303 · Cited by 114
Genetic studies on cystic fibrosis in Hawaii.
Wright, S. W., & Morton, N. E. (1968) · PubMed · Cited by 110
Stahel, R. A., Gilks, W. R., Lehmann, H., et al. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570704 · Cited by 110
KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts
Ohshimo, S., Yokoyama, A., Hattori, N., Ishikawa, N., Hirasawa, Y., & Kohno, N. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.144 · Cited by 110
Self-citationBonella, F., Volpe, A., Caramaschi, P., et al. (2011) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 92
Clinical Utility of Serum .BETA.-D-Glucan and KL-6 Levels in Pneumocystis jirovecii Pneumonia
Nakamura, H., Tateyama, M., Tasato, D., Haranaga, S., Yara, S., Higa, F., Ohtsuki, Y., & Fujita, J. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.1680 · Cited by 88
Serum biomarkers in interstitial lung diseases
Τzouvelekis, Α., Kouliatsis, G., Anevlavis, S., & Bouros, D. E. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-78 · Cited by 88
Janssen, R., Sato, H., Grutters, J. C., et al. (2003) · CHEST Journal · doi:10.1378/chest.124.6.2119 · Cited by 81
Yanaba, K., Hasegawa, M., Hamaguchi, Y., et al. (2004) · PubMed · Cited by 77
Yamane, K., Ihn, H., Kubo, M., et al. (2000) · PubMed · Cited by 75
Non‐invasive biomarkers in pulmonary fibrosis
Prasse, A., & Müller–Quernheim, J. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01600.x · Cited by 74
Review: Therapies for interstitial lung disease: past, present and future
Kim, R., & Meyer, K. C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096948 · Cited by 66
Inata, J., Hattori, N., Yokoyama, A., Ohshimo, S., Doi, M., Ishikawa, N., Hamada, H., & Kohno, N. (2007) · International Journal of Cancer · doi:10.1002/ijc.22613 · Cited by 50
Self-citationIshikawa, N., Hattori, N., Yokoyama, A., Tanaka, S., Nishino, R., Yoshioka, K., Ohshimo, S., Fujitaka, K., Ohnishi, H., Hamada, H., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23411 · Cited by 49
Self-citationSerum biomarkers in idiopathic pulmonary fibrosis
van den Blink, B., Wijsenbeek, M. S., & Hoogsteden, H. C. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.08.001 · Cited by 48
Shimizu, Y., Sunaga, N., Dobashi, K., Fueki, M., Fueki, N., Makino, S., & Mori, M. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-47 · Cited by 47
Kondo, T., Hattori, N., Ishikawa, N., Murai, H., Haruta, Y., Hirohashi, N., Tanigawa, K., & Kohno, N. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-32 · Cited by 46
Self-citationInagaki, Y., Xu, H., Nakata, M., Seyama, Y., Hasegawa, K., Sugawara, Y., Tang, W., & Kokudo, N. (2009) · PubMed · Cited by 45
KL-6 as a Serologic Indicator of Pneumocystis carinii Pneumonia in Immunocompromised Hosts.
Hamada, H., Kohno, N., Yokoyama, A., Hirasawa, Y., Hiwada, K., Sakatani, M., & Ueda, E. (1998) · Internal Medicine · doi:10.2169/internalmedicine.37.307 · Cited by 39
Self-citationAgeing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma
Ishikawa, N., Mazur, W., Toljamo, T., Vuopala, K. S., Rönty, M. J., Horimasu, Y., Kohno, N., & Kinnula, V. L. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-22 · Cited by 36
Self-citationClinical use of biomarkers of survival in pulmonary fibrosis
Thomeer, M., Grutters, J. C., Wuyts, W. A., Willems, S., & Demedts, M. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-89 · Cited by 35
Predicting prognosis in idiopathic pulmonary fibrosis.
Barlo, N. P., van Moorsel, C. H. M., van den Bosch, J. M. M., & Grutters, J. C. (2010) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 31
Proteomic approaches for studying human parenchymal lung diseases
Kinnula, V. L., Ishikawa, N., Bergmann, U., & Ohlmeier, S. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.80 · Cited by 23
Self-citationHisata, S., Kimura, Y., Shibata, N., Ono, S., Kobayashi, T., Chiba, S., Ohta, H., Nukiwa, T., & Ebina, M. (2010) · Pulmonary Medicine · doi:10.1155/2011/806014 · Cited by 21
Nakashima, T., Yokoyama, A., Ohnishi, H., Hamada, H., Ishikawa, N., Haruta, Y., Hattori, N., Tanigawa, K., & Kohno, N. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01929.x · Cited by 20
Self-citationSerum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis.
Ohshimo, S., Bonella, F., Grammann, N., Starke, K., Cui, A., Bauer, P. C., Teschler, H., Kohno, N., Guzmán, J. C., & Costabel, U. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 19
Self-citationNakashima, T., Yokoyama, A., Inata, J., Ishikawa, N., Haruta, Y., Hattori, N., & Kohno, N. (2010) · CHEST Journal · doi:10.1378/chest.09-3082 · Cited by 18
Self-citationHypersensitivity pneumonitis caused by Penicillium citrinum, not enoki spores
Yoshikawa, S., Tsushima, K., Yasuo, M., Fujimoto, K., Kubo, K., Kumagai, T., & Yamazaki, Y. (2007) · American Journal of Industrial Medicine · doi:10.1002/ajim.20535 · Cited by 16
Differential expression of the glycosylated forms of MUC1 during lung development.
Sakurai, J., Hattori, N., Nakajima, M., Moriya, T., Suzuki, T., Yokoyama, A., & Kohno, N. (2007) · PubMed · doi:10.4081/1130 · Cited by 14
Self-citationIshikawa, N., Kondo, K., Oguri, T., et al. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.381 · Cited by 5
Self-citation
Cited by
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
Ballester, B., Milara, J., & Cortijo, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27526 · Cited by 43
Metadata
- Authors
- Ishikawa, N., Hattori, N., Yokoyama, A., & Kohno, N.
- Venue
- Respiratory Investigation
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 50
- Issue
- 1
- Pages
- 3-13
- ISSN
- 2212-5345 (ISSN-L)
- OpenAlex
- W2108581097
- Cited by
- 402
- References
- 65
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.